Equillium, Inc. (NASDAQ:EQ) Insider Penny Tom Sells 38,806 Shares

Equillium, Inc. (NASDAQ:EQ) insider Penny Tom sold 38,806 shares of the business’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $0.85, for a total transaction of $32,985.10. Following the completion of the sale, the insider now directly owns 10,051 shares of the company’s stock, valued at approximately $8,543.35. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Equillium Trading Down 0.6 %

NASDAQ:EQ opened at $0.86 on Wednesday. The stock has a 50 day moving average of $0.86 and a two-hundred day moving average of $1.34. Equillium, Inc. has a 12 month low of $0.45 and a 12 month high of $3.25. The firm has a market cap of $30.14 million, a P/E ratio of -2.38 and a beta of 1.84.

Equillium (NASDAQ:EQ) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.16. Equillium had a negative return on equity of 36.88% and a negative net margin of 19.51%. The firm had revenue of $13.85 million for the quarter, compared to analyst estimates of $8.15 million. On average, research analysts forecast that Equillium, Inc. will post -0.14 earnings per share for the current year.

Institutional Investors Weigh In On Equillium

A number of large investors have recently modified their holdings of the business. Acadian Asset Management LLC purchased a new position in shares of Equillium in the first quarter worth about $249,000. Renaissance Technologies LLC boosted its holdings in shares of Equillium by 43.6% during the 2nd quarter. Renaissance Technologies LLC now owns 300,400 shares of the company’s stock worth $208,000 after purchasing an additional 91,200 shares during the last quarter. Finally, Decheng Capital LLC purchased a new stake in shares of Equillium in the fourth quarter valued at approximately $3,215,000. Hedge funds and other institutional investors own 27.05% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Equillium in a research report on Monday, August 19th.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.